Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$12.66 USD

12.66
254,121

+0.02 (0.16%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $12.68 +0.02 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat

by Zacks Equity Research

Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.

    Zacks Equity Research

    Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down

    by Zacks Equity Research

    Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.

      Zacks Equity Research

      Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down

      by Zacks Equity Research

      Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.

        Zacks Equity Research

        Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss

        by Zacks Equity Research

        Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.

          Zacks Equity Research

          Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up

          by Zacks Equity Research

          Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.

            Zacks Equity Research

            Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses

            by Zacks Equity Research

            Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.

              Zacks Equity Research

              Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus

              by Zacks Equity Research

              Ophthotech (OPHT) reports narrower year-over-year loss for the first quarter.

                Zacks Equity Research

                VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters

                by Zacks Equity Research

                VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.

                  Zacks Equity Research

                  Will Agency Growth Aid Booking Holdings (BKNG) Q1 Earnings?

                  by Zacks Equity Research

                  Booking Holdings' (BKNG) Q1 earnings are likely to reflect growth in international markets.

                    Zacks Equity Research

                    ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat

                    by Zacks Equity Research

                    ImmunoGen (IMGN) reports wider-than-expected loss in Q1. Lower license and milestone fees resulted in substantial decrease in year-over-revenues.